Dixumab can be administered subcutaneously in the arm, thigh, abdomen and other parts of the body.
Dixumab is a human IgG2 monoclonal antibody class of drugs, mainly used for patients with non-surgically resectable or surgically resected osteoblastoma leaving dysfunction, and can only be treated by subcutaneous administration, which is usually clinically administered by injection in the abdomen, thighs, arms, and other parts of the body.
Dixumab can bind to RANKL in the body, preventing RANK ligands from activating RANK on the surface of osteoblasts, and at the same time reducing the activation and development of osteoblasts as well as bone resorption, allowing the bones to be rebuilt, and improving the patient’s condition.
During the medication period, some patients may experience adverse reactions such as headache, back pain, headache, and osteonecrosis of the jaw, and need to closely observe the patient’s condition; in addition, hypocalcemia needs to be treated before using the drug.
Please strictly follow the doctor’s instructions, do not self-medication.